Authors

Michael J. Ricciardi, Mabloc LLC
Lauren N. Rust, Oregon Health and Science University
Nuria Pedreño-Lopez, George Washington University
Sofiya Yusova, Oregon Health and Science University
Sreya Biswas, Oregon Health and Science University
Gabriela M. Webb, Oregon Health and Science University
Lucas Gonzalez-Nieto, University of Miami
Thomas B. Voigt, Mabloc LLC
Johan J. Louw, George Washington University
Fernanda D. Laurino, Mabloc LLC
John R. DiBello, Mabloc LLC
Hans-Peter Raué, Oregon National Primate Research Center
Aaron M. Barber-Axthelm, Oregon National Primate Research Center
Kimberly Chun, Oregon National Primate Research Center
Samantha Uttke, Oregon National Primate Research Center
Lidiane M. S. Raphael, Instituto Oswaldo Cruz
Aaron Yrizarry-Medina, George Washington University
Brandon C. Rosen, University of Miami
Rebecca Agnor, Oregon National Primate Research Center
Lina Gao, Oregon National Primate Research Center
Caralyn Labriola, Oregon Health and Science University
Michael Axthelm, Oregon National Primate Research Center
Jeremy Smedley, Oregon National Primate Research Center
Justin G. Julander, Utah State University
Myrna C. Bonaldo, Instituto Oswaldo Cruz
Laura M. Walker, Adagio Therapeutics Inc.
Ilhem Messaoudi, University of KentuckyFollow
Mark K. Slifka, Oregon National Primate Research Center
Dennis R. Burton, Mabloc LLC
Esper G. Kallas, Mabloc LLC
Jonah B. Sacha, Mabloc LLC
David I. Watkins, Mabloc LLC
Benjamin J. Burwitz, Oregon Health and Science UniversityFollow

Abstract

Yellow fever virus (YFV) is a reemerging global health threat, driven by several factors, including increased spread of the mosquito vector and rapid urbanization. Although a prophylactic vaccine exists, vaccine hesitancy, supply deficits, and distribution difficulties leave specific populations at risk of severe YFV disease, as evidenced by recent outbreaks in South America. To establish a treatment for patients with severe YFV infection, we tested 37 YFV-specific monoclonal antibodies isolated from vaccinated humans and identified two capable of potently neutralizing multiple pathogenic primary YFV isolates. Using both hamster and nonhuman primate models of lethal YFV infection, we demonstrate that a single administration of either of these two potently neutralizing antibodies during acute infection fully controlled viremia and prevented severe disease and death in treated animals. Given the potential severity of YFV-induced disease, our results show that these antibodies could be effective in saving lives and fill a much-needed void in managing YFV cases during outbreaks.

Document Type

Article

Publication Date

2023

Notes/Citation Information

Copyright © 2023 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Digital Object Identifier (DOI)

https://doi.org/10.1126/scitranslmed.ade5795

Funding Information

This work was supported by NIH grants R42 AI155275 and P51 OD011092 and by Mabloc LLC.

Share

COinS